Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer

Authors:

Open Access

Publisher website

15 July 2025

other
Published by American Association for Cancer Research (AACR)

DOI:10.1158/1078-0432.29568104

Abstract

Supplementary Table 2. Representativeness of study participants.

Keywords